Innovation

15 posts

Do not Accept partial results about PH-Like Acute Lymphoblastic Leukemia

DNA RNA ALL

Distinguishing PH-like acute lymphoblastic leukemia (ALL) from other types of ALL relies on full evaluation of the molecular abnormalities in the leukemic cells. Order GTC Hematology Molecular Profile Plus GTC Hematology Profile Plus and obtain complete evaluation of mutations in DNA of 177 genes and fusion/expression/mutations in RNA of 1408 genes. Here is an example […]

Read More

Time Matters on Health Tests [TAT-NGS]

Turn Around Time, Turnaround Time, TAT, NGS (Next Generation Sequencing), Next-Gen, NGS, TTI (Time to Treatment Initiation), GTC

We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay leads to a worse outcome Patients with cancer who have to wait longer for treatment suffer from significant anxiety and stress Physicians and patients deserve to get the results of […]

Read More

Looking for an answer quickly from your NGS provider?

fast reliable NGS testing for cancer

Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible.  Are you waiting 21-28 days to receive your NGS results? Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 7 days of receiving the sample.  GTC tests […]

Read More

CSI Laboratories is the first to offer 177 gene liquid biopsy for hematology

CSI Laboratories is a specialized cancer diagnostics center

-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC)  Membership in the Co-Op also makes CSI Laboratories the first to offer 177 gene liquid biopsy for hematology   ALPHARETTA –   CSI Laboratories, nationally renowned for its quality cancer diagnostics, goes a step forward to precision […]

Read More

Acute Lymphoblastic Leukemia | Just published: A consensus of North American experts

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. In these patients, relapse occurs despite achievement of morphologic remission (ie, […]

Read More

Eltrombopag Improves Hematopoiesis

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome(MDS) Program: Oral and Poster Abstracts | Saturday, December 1, 2018: 4:00 PM Session: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics I Eltrombopag (EPAG), a thrombopoietin receptor agonist, has been shown […]

Read More

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers | ASH ANNUAL MEETING ABSTRACT

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib Program: Oral and Poster Abstracts | Monday, December 3, 2018: 11:45 AM Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: Advances […]

Read More

Acute Myeloid Leukemia | ASH Annual Meeting Abstract

Acute Myeloid Leukemia

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Saturday, December 1, 2018, 6:15 PM-8:15 PM | Hall GH (San Diego Convention Center) Background: Acute […]

Read More

Press Release – Genomic Testing Cooperative

NGS innovation

Genomic Testing Cooperative, a Limited Cooperative Association, Launches a New Platform for Affordable Genomic Cancer Profiling Irvine, California-November 1, 2018 – Genomic Testing Cooperative (GTC), a Limited Cooperative Association, announced today that it will offer multiple laboratory-developed genomic profiling tests for hematologic and solid tumors using next-generation sequencing (NGS) technology. The Co-Op provides a first […]

Read More